Ty-Jour t1 - 毒蕈碱M1-受体选择性拮抗剂，Telenzepine，COPD患者没有支气管扩张作用JF - 欧洲呼吸期刊Jo - Eur Respir J SP - 378 LP - 382 VL - 6是 - 3 Au - Ukena，DAU - Wehinger，C Au - Engelstatter，R Au - Steinijans，V Au - Sybrecht，GW Y1 - 1993/03/01 UR - //www.qdcxjkg.com/content/6/3/378.abstract n2 -In a double-blind, placebo-controlled, randomized, cross-over trial, we studied the effects of the muscarinic M1-receptor-selective antagonist (+/-)-telenzepine (3 mg orally at 6 p.m. for 5 days) in 21 patients with chronic obstructive pulmonary disease (COPD). At enrollment all patients showed at least a 50% decrease in airway resistance (Raw) after inhalation of 400 micrograms fenoterol or 200 micrograms oxitropium bromide. Telenzepine did not have a significant effect on forced expiratory volume in one second (FEV1) or forced vital capacity (FVC). Also, no significant changes could be detected in daily spirometric profiles or Raw. The results indicate that short-term treatment with the M1-selective antagonist, telenzepine, does not improve airway function in COPD patients, at least after administration by the oral route. ER -